Premium
A COMPARISON OF THE METABOLIC EFFECTS OF FLOSEQUINAN AND PROPRANOLOL IN PATIENTS WITH NON‐INSULIN‐DEPENDENT DIABETES MELLITUS
Author(s) -
Lewis H. M.,
Kendall M. J.,
Wright A. D.,
Bratty J. R.,
Maxwell S.
Publication year - 1991
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.1991.tb00299.x
Subject(s) - medicine , propranolol , placebo , endocrinology , crossover study , diabetes mellitus , insulin , triglyceride , vasodilation , adverse effect , cholesterol , alternative medicine , pathology
Summary The effects of steady‐state fiosequinan, a new peripheral vasodilator, and propranolol on glucose tolerance and plasma lipids in 22 non‐insulin‐dependent diabetics were investigated in a randomized double‐blind placebo‐controlled, three‐way crossover trial. Fiosequinan produced no impairment of glucose tolerance compared with placebo. Propranolol produced significant increases in fasting plasma glucose ( P < 0·01) and increases in the area under the glucose tolerance curve ( P < 0·05) compared to placebo. No significant effects on cholesterol levels were seen on either treatment but triglyceride levels were significantly elevated on propranolol compared with placebo ( P <0·01). These data suggest that fiosequinan, used in therapeutic dosage, has no adverse metabolic effects on the non‐insulin‐dependent diabetic and this may be an advantage for a drug used in the treatment of hypertension or congestive heart failure.